Translational medicine

Leader of the research programme:

Professor Jiří Ehrman, MD., PhD.
Professor Vladimír Mihál, MD., PhD.

Translational Medicine research program is removing barriers to multi-disciplinary collaboration, attracts attention of researchers
to clinically relevant problems and validates discoveries from molecular target, biomarker and drug discovery
pipelines to proof-of concept clinical trials. By enabling physicians, chemistries, and pharmacologists to leverage biology
technologies, translation medicine program facilitates early detection of cancer and other diseases, increases efficiency
in drug development, improves drug efficacy and enables personalized medicine. The program collects and comparatively
analyzes clinical information, including data contained in hospital and/or national registries and medical records, laboratory
and imaging reports, etc. The research program supports for clinical trials phase I-III in specific patient populations, including
healthy volunteers, pediatric population, disease specific populations, etc. The primary interest is put on proof-of-concept
clinical trials phase I-IIa, pharmacokinetics and biomarker oriented clinical trials. However we perform also bioequivalence
clinical trials in generics and biosimilars.

Deliverables: 1. Clinical biomarker validation studies; 2. Drugs tested in proof-of-concept clinical trials. Deliverables will be published in the form of papers, research reports, patents and conference presentations.

Key methodological approaches: Genomics, proteomics, metabolomics, bioanalytics, validation clinical studies and proof-of concept clinical studies, bioinformatics and biostatistics.